Replies to post #115378 on Biotech Values

[genisi]

I disagree with the implication that Denosumab cannot extend survival and with the assertion that Denosumab is not an “anti-cancer” drug.

The results from the Alpharadin (radium-223 chloride) trial #msg-63944830 show that a bone targeted therapy (not an “anti-cancer” drug) can improve OS in CRPC patients with bone metastases.